Role of initial and follow-up IL-6 (Interleukin-6) titre in COVID-19 pneumonia: A single center experience-Reference-Cited by-同舟云学术

Role of initial and follow-up IL-6 (Interleukin-6) titre in COVID-19 pneumonia: A single center experience

Published:2022-06-29 Issue:5 Volume:19 Page:em390
ISSN:2516-3507
Container-title:Electronic Journal of General Medicine
language:
Short-container-title:ELECTRON J GEN MED

Author:

Patil Shital Vishnu^ORCID,Gondhali Gajanan^ORCID,Acharya Abhijit^ORCID

Publisher

Modestum Ltd

Subject

General Medicine

Link

https://www.ejgm.co.uk/download/role-of-initial-and-follow-up-il-6-interleukin-6-titre-in-covid-19-pneumonia-a-single-center-12191.pdf

Reference42 articles.

1. WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (Accessed: 24 December 2021).

2. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020;58(7):1063-9. https://doi.org/10.1515/cclm-2020-0240 PMid:32191623

3. Bohn MK, Lippi G, Horvath A, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med. 2020;58:1037-52. https://doi.org/10.1515/cclm-2020-0722 PMid:32459192

4. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56(4):2003006. https://doi.org/10.1183/13993003.03006-2020 PMid:32883678 PMCid:PMC7474149

5. Lau CS, Hoo SP, Koh JMJ, Phua SK, Aw TC. Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms. J Virol Methods. 2021;296:114224. https://doi.org/10.1016/j.jviromet.2021.114224 PMid:34214571 PMCid:PMC8240448

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of IL-6 as ‘core inflammatory marker’ in assessment of severity, response to therapy and predicting outcome in COVID-19 pneumonia: A single center experience of 2400 cases in tertiary care setting in India;Sri Ramachandra Journal of Health Sciences;2024-01-04

2. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients;Cytokine;2024-01

3. Persistent residual lung abnormalities as final outcome in recovered severe COVID-19 pneumonia with lung function abnormalities in spirometry: Pulmonologist and radiologist perspective;The Journal of Association of Chest Physicians;2024-01

4. Progressive residual lung abnormalities as final outcome in recovered severe COVID-19 pneumonia with lung function abnormalities in spirometry: Pulmonologist and radiologist perspective;Muller Journal of Medical Sciences and Research;2024-01

5. Residual lung abnormalities in recovered COVID-19 cases at 1-year follow-up: A single-center final radiological outcome phenotype study in India;Radiology of Infectious Diseases;2023-12